{"nctId":"NCT01167140","briefTitle":"Cryo-Touch II for the Treatment of Wrinkles","startDateStruct":{"date":"2010-07"},"conditions":["Facial Wrinkles"],"count":42,"armGroups":[{"label":"Cryo-Touch II","type":"EXPERIMENTAL","interventionNames":["Device: Cryo-Touch II"]}],"interventions":[{"name":"Cryo-Touch II","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 30-70 years\n* Subject has a glabellar and/or forehead wrinkle rating by investigator of at least 1 at rest on the 5-point Wrinkle Scale (5WS)\\*\n* Subject has signed IRB-approved informed consent form\n\nExclusion Criteria:\n\n* Subject takes any medication or dietary supplement regularly that affects blood clotting (e.g., Coumadin, aspirin, clopidogrel) or increases the risk of bleeding/bruising\n* Subject has had prior surgery that alters the subcutaneous anatomy of the target treatment sites\n* The investigator is unable to substantially lessen facial lines by physical separation\n* Subject has undergone another facial cosmetic procedures at or above the level of the cheekbones within the past 6 months\n* Subject is participating in another facial cosmetic research study\n\nPatient has any of following conditions:\n\n* History of facial nerve palsy\n* Marked facial asymmetry\n* Ptosis\n* Excessive dermatochalasis\n* Deep dermal scarring\n* Thick sebaceous skin\n* History of neuromuscular disorder\n* Chronic dry eye symptoms\n* Allergy or intolerance to lidocaine","healthyVolunteers":true,"sex":"ALL","minimumAge":"30 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Effectiveness and Safety Success","description":"* Effectiveness success: an improvement in line severity in the target area in animation at 30 days post-treatment as rated by the investigator using the 5-point wrinkle scale\n* Safety success: the absence of a device-related serious adverse event (DSAE)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With One Point Improvement in Line Severity","description":"• Investigators' rating of line severity improvement in the target area in animation at 7 days post-treatment, and at 30-day intervals for 120 days after treatment from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With an Improvement in Global Appearance","description":"• Subjects' global assessment of change in appearance of target area at 7 days post-treatment, and at 30-day intervals for 120 days after treatment to baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["local side effect","headache"]}}}